Journal Article

Recurrent acute pancreatitis prevention by the elimination of alcohol and cigarette smoking (REAPPEAR): protocol of a randomised controlled trial and a cohort study

Zemplényi, Antal, Mirabella, Antonello, Zádori, Noémi, Szakó, Lajos, Zatorski, Hubert, Szakács, Zsolt, Capurso, Gabriele, Hegyi, Péter, Susak, Yaroslav, Czakó, László, Gheorghe, Cristian, Farkas, Nelli, Ocskay, Klementina, Birkás, Béla, Apadula, Laura, Saizu, Ionut Adrian, Petersen, Ole H, Małecka-Panas, Ewa, Juhász, Márk Félix, Gajdán, László, Opalchuk, Kristina, Czopf, László, Papp, Mária, de-Madaria, Enrique, Rosendahl, Jonas, Nagy, Tamás, Párniczky, Andrea, Hartung, István, Illés, Dóra, Csathó, Árpád, Miklós, Emőke, Szentesi, Andrea, Erőss, Bálint, Marino, Marco V, Izbéki, Ferenc

2022

Overview

Background/objectivesAcute recurrent pancreatitis (ARP) due to alcohol and/or tobacco abuse is a preventable disease which lowers quality of life and can lead to chronic pancreatitis. The REAPPEAR study aims to investigate whether a combined patient education and cessation programme for smoking and alcohol prevents ARP.Methods and analysisThe REAPPEAR study consists of an international multicentre randomised controlled trial (REAPPEAR-T) testing the efficacy of a cessation programme on alcohol and smoking and a prospective cohort study (REAPPEAR-C) assessing the effects of change in alcohol consumption and smoking (irrespective of intervention). Daily smoker patients hospitalised with alcohol-induced acute pancreatitis (AP) will be enrolled. All patients will receive a standard intervention priorly to encourage alcohol and smoking cessation. Participants will be subjected to laboratory testing, measurement of blood pressure and body mass index and will provide blood, hair and urine samples for later biomarker analysis. Addiction, motivation to change, socioeconomic status and quality of life will be evaluated with questionnaires. In the trial, patients will be randomised either to the cessation programme with 3-monthly visits or to the control group with annual visits. Participants of the cessation programme will receive a brief intervention at every visit with direct feedback on their alcohol consumption based on laboratory results. The primary endpoint will be the composite of 2-year all-cause recurrence rate of AP and/or 2-year all-cause mortality. The cost-effectiveness of the cessation programme will be evaluated. An estimated 182 participants will be enrolled per group to the REAPPEAR-T with further enrolment to the cohort.Ethics and disseminationThe study was approved by the Scientific and Research Ethics Committee of the Hungarian Medical Research Council (40394-10/2020/EÜIG), all local ethical approvals are in place. Results will be disseminated at conferences and in peer-reviewed journals.Trial registration numberNCT04647097

• Publisher: British Medical Journal Publishing Group,BMJ Publishing Group LTD,BMJ Publishing Group
• Subject: Alcohol use / Cohort analysis / Gastroenterology and Hepatology / Intervention / Motivation / pancreatic disease / Pancreatitis / Patients / Prevention / preventive medicine / Smoking cessation / substance misuse